Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
about
X-ray structure of p38α bound to TAK-715: comparison with three classic inhibitorsThe p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.Tandem mass spectrometry study of p38α kinase inhibitors and related substances.A new strategy for the synthesis of β-benzylmercaptoethylamine derivativesMacrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinaseTNFalpha blockade in human diseases: mechanisms and future directions.Discontinued drugs in 2006: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs.Targeting signaling pathways with small molecules to treat autoimmune disorders.p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).Solvent-free and catalysts-free chemistry: a benign pathway to sustainability.Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.Synthesis and Regioselective Reaction of Some Unsymmetrical Heterocyclic Chalcone Derivatives and Spiro Heterocyclic Compounds as Antibacterial Agents.Synthetic phosphorylation of p38α recapitulates protein kinase activitytert-Butyl N-benzyl-N-[4-(4-fluoro-benzoyl-meth-yl)-2-pyrid-yl]carbamatetert-Butyl N-benzyl-N-(4-methyl-2-pyrid-yl)carbamate.Development of an online p38α mitogen-activated protein kinase binding assay and integration of LC-HR-MS.Thiazole formation through a modified Gewald reaction.
P2860
Q27681911-2D8D7C74-02E1-48B4-AFB8-D2FACD87A430Q33393902-873EEA70-F174-405F-A8A0-D8AFC782C44EQ34748950-6D6E2FCF-343A-4983-8144-AFC84CE54C42Q34760322-2C258F56-A0B0-4C7D-BD19-8869BD3FD9F5Q35828722-1E705967-A114-4274-8DD9-313FACBD7980Q36536886-268963B7-70BF-4153-BDF9-21CD02127493Q36916853-484D0C47-4226-4525-9D76-67E167E060F8Q37755216-E4E758A0-338B-4FD0-B21E-41AFDDC39DD8Q37955936-E0F6E84D-E777-45EC-A70C-33D6A38BEE23Q38172889-23A94011-4FD0-433B-9E54-4B1F172ED0FBQ38701634-6A2229C8-155C-46EB-BFE0-52F628DCAF53Q40185627-A712CB98-3841-473C-90BE-BEBD130974DFQ41889780-A3C8FEA5-402C-49DE-A1BD-F371AD21BE82Q42091734-16786044-ACD9-4311-B8E2-758CAB3F328FQ42406468-A9664E53-4A65-490F-AEA3-FB7DED2286AAQ42423587-61C64474-2B23-43B6-ACE6-AAE764866204Q42526746-FE1AC8C3-8D69-414A-BBE1-EDC5AB42F5AC
P2860
Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Novel inhibitor of p38 MAP kin ...... ti-rheumatoid arthritis agent.
@en
type
label
Novel inhibitor of p38 MAP kin ...... ti-rheumatoid arthritis agent.
@en
prefLabel
Novel inhibitor of p38 MAP kin ...... ti-rheumatoid arthritis agent.
@en
P2093
P356
P1476
Novel inhibitor of p38 MAP kin ...... ti-rheumatoid arthritis agent.
@en
P2093
Etsuo Kotani
Hiroyuki Kimura
Ken-Ichi Naruo
Maki Miyamoto
Satoru Asahi
Seiji Miwatashi
Shigenori Ohkawa
Toshimasa Tanaka
Yasuyoshi Arikawa
P304
P356
10.1021/JM050165O
P407
P577
2005-09-01T00:00:00Z